Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders.
Type
Public
HQ
New Haven, US
Founded
1992
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US
Report incorrect company information

Key People/Management at Alexion Pharmaceuticals

LUDWIG HANTSON

LUDWIG HANTSON

Chief Executive Officer
Ludwig Hantson

Ludwig Hantson

Chief Executive Officer
David Brennan

David Brennan

Chairman
J.D Ann Veneman

J.D Ann Veneman

Director
Felix Baker

Felix Baker

Director
M. Burns

M. Burns

Director
Christopher Coughlin

Christopher Coughlin

Director
Paul Friedman

Paul Friedman

Director
John Mollen

John Mollen

Director
Francois Nader

Francois Nader

Director
Alvin Parven

Alvin Parven

Director
Andreas Rummelt

Andreas Rummelt

Director
Dave Anderson

Dave Anderson

Executive Vice President, Chief Financial Officer
Brian Goff

Brian Goff

Executive Vice President, Chief Commercial Officer
John Orloff

John Orloff

Executive Vice President, Head of Research & Development
J.D Indrani Franchini

J.D Indrani Franchini

Executive Vice President, Chief Compliance Officer
Anne-Marie Law

Anne-Marie Law

Executive Vice President, Chief Human Resources Officer
J.D John Moriarty

J.D John Moriarty

Executive Vice President, General Counsel

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has an office in Washington, Brussels, Athens, Vienna and in 26 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse
Show all (31)
Report incorrect company information

Alexion Pharmaceuticals Financials and Metrics

Alexion Pharmaceuticals Financials

Alexion Pharmaceuticals's revenue was reported to be $3.08 b in FY, 2016 which is a 18.4% increase from the previous period.
USD

Revenue (Q3, 2017)

859 m

Gross profit (Q3, 2017)

702 m

Gross profit margin (Q3, 2017), %

81.7%

Net income (Q3, 2017)

78 m

EBIT (Q3, 2017)

80 m

Market capitalization (5-Feb-2018)

27.2 b

Cash (4-Feb-2018)

550 m

EV

26.8 b
Alexion Pharmaceuticals's current market capitalization is $27.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.6 b2.2 b2.6 b3.1 b

Revenue growth, %

44%17%18%

Cost of goods sold

233.1 m258 m

Gross profit

2.4 b2.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

636.2 m666.6 m701 m753.1 m799.1 m870 m912 m859 m

Cost of goods sold

51.4 m32.9 m39.6 m51.9 m69.4 m52 m54.1 m59 m60.6 m71.1 m69 m84 m157 m

Gross profit

584.2 m612.6 m642.1 m692.5 m728 m801 m828 m702 m

Gross profit Margin, %

92%92%92%92%91%92%91%82%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

529.9 m944 m1 b966 m

Accounts Receivable

650 m

Inventories

102.6 m176.4 m289.9 m375 m

Current Assets

2.2 b2.8 b2.4 b2.6 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

910.4 m528.3 m612 m752.2 m916.8 m1.3 b1.2 b710.2 m597.6 m762 m713 m542 m550 m

Accounts Receivable

405 m429 m440.7 m436.5 m479.9 m535.8 m512.3 m586.2 m609.3 m676.8 m660 m710 m705 m

Inventories

105.2 m126.2 m144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m410 m441 m

Current Assets

1.9 b2.2 b2.3 b2.6 b2.9 b2.5 b2.5 b2.1 b2.4 b2.6 b2.7 b2.8 b2.9 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

252.9 m656.9 m144.4 m399 m

Depreciation and Amortization

28.7 m46.9 m166.6 m396 m

Inventories

126 k(67 m)(88 m)(84 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

93.8 m159.4 m166.5 m177.7 m91.3 m261.5 m77.8 m92.2 m207.1 m306.6 m170 m335 m413 m

Depreciation and Amortization

23.1 m72.9 m96.8 m194.6 m295.3 m99 m201 m311 m

Inventories

144.9 m140 m174.5 m4.7 m(7.4 m)(3.8 m)(39 m)(72.2 m)(19 m)(33 m)(69 m)

Accounts Payable

36.1 m23.2 m52.9 m47 m47 m42.9 m29 m44.8 m61 m
USDY, 2017

EV/EBIT

334.6 x

EV/CFO

31.2 x

Revenue/Employee

275.2 k

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information